Valuation : Nuvectra Corporation

Market Cap 1.7M 1.46M 1.38M 1.25M 2.35M 162M 2.36M 16.32M 6.31M 82.37M 6.38M 6.24M 261M P/E 2017
-1.84x
P/E 2018 -5.02x
Enterprise Value -53.46M -46M -43.31M -39.47M -73.84M -5.09B -74.14M -513M -198M -2.59B -201M -196M -8.21B EV / Sales 2017
2.58x
EV / Sales 2018 4.76x
Free-Float
96.76%
Yield 2017 *
-
Yield 2018 -
Manager TitleAgeSince
Chief Executive Officer 78 31/01/2019
Compliance Officer 51 01/01/2015
Director TitleAgeSince
Director/Board Member 67 01/03/2016
Director/Board Member 78 01/03/2016
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+16.67% - - 268K
+0.23%-4.35%-19.92%+3.13% 183B
+0.04%+0.18%-1.83%+13.45% 118B
+0.29%-3.29%+8.91%+83.02% 61.96B
-0.49%-6.75%+11.83%+44.52% 50.6B
+0.70%-4.37%-5.86%-32.88% 48.78B
+0.13%-5.93%+7.61%-21.36% 31.9B
-0.95%-5.36% - - 30.44B
+0.24%-1.22%+34.29%-14.78% 23.77B
-2.51%-10.87%-14.66%+6.30% 22.26B
Average -0.24%-0.79%+2.55%+10.18% 57.05B
Weighted average by Cap. -0.03%-1.89%-4.18%+13.08%

Financials

2017 2018
Net sales 31.84M 27.39M 25.79M 23.5M 43.98M 3.03B 44.15M 306M 118M 1.54B 120M 117M 4.89B 48.83M 42.02M 39.56M 36.05M 67.45M 4.65B 67.72M 469M 181M 2.37B 183M 179M 7.5B
Net income -44.6M -38.38M -36.14M -32.93M -61.61M -4.24B -61.85M -428M -166M -2.16B -167M -164M -6.85B -48.13M -41.42M -39M -35.53M -66.48M -4.58B -66.75M -462M -179M -2.33B -181M -177M -7.39B
Net Debt -1.49M -1.28M -1.21M -1.1M -2.06M -142M -2.07M -14.31M -5.53M -72.23M -5.59M -5.47M -229M -55.16M -47.46M -44.69M -40.72M -76.19M -5.25B -76.49M -530M -205M -2.67B -207M -203M -8.47B
Logo Nuvectra Corporation
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company's Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company's commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company's neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).
Employees
-
  1. Stock Market
  2. Stocks
  3. NVTRQ Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!